Skip to content
Biotechnology

Cleo Delivers Early Progress on Development Program

Cleo Diagnostics Ltd ASX.COV 2 mins read

Highlights

  • Selection of biomarkers panel for Cleo’s ovarian cancer test-kit has been finalised
  • Antibody development has advanced increasing confidence for commercial assay development and upscaling for commercial manufacturing
  • The Company is in final stages evaluating four commercial antibody manufacturing partners


MELBOURNE, AUSTRALIA, 9 October, 2023: Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) confirms the delivery of early milestones in its development program targeting the initial surgical triage test market for its simple and accurate blood test.


TEST-KIT BIOMARKERS PANEL FINALISED
Cleo has finalised the selection of biomarkers to be used in its ovarian cancer test-kit, along with completing the development for a prototype of the proprietary scoring algorithm. The performance metrics of the test were evaluated in a clinical study of 334 patients, the results of which are being prepared for publication in a peer-reviewed medical journal. The Company expects the publication outcome to be reported to the market by the end of CY2023. The data cannot be released prior to publication due to the nature of the peer-review process. Concurrently, Cleo is also preparing a further patent application based on the findings.

ANTIBODY DEVELOPMENT
A key objective for the Company is to develop its own antibodies and target proteins which will allow control of supply, quality, cost and high-performance of key reagents that will underpin the consistent and reliable manufacture of test-kits. Cleo can confirm that Surface Plasmon Resonance Analysis has shown that the core antibodies of the CXCL10 active ratio test are binding to their respective targets with high affinity and are suitable for commercial assay development and upscaling in commercial manufacturing. Hybridomas to produce the supporting biomarker antibodies are also well progressed, with expected completion of the full test-kit panel in Q2 CY2024.

Commenting on the early development progress, CLEO Chief Executive, Richard Allman, said:
“The commercial foundation for our ovarian cancer test-kit targeting the initial surgical triage market is coming together quickly.
We are running a number of initiatives in parallel which are designed to place the Company in a strong position to achieve key milestones set this financial year.”

SELECTION PROCESS FOR ANTIBODY MANUFACTURING PARTNER
Cleo is in the late stages of evaluating four commercial antibody manufacturing partners as part of a robust tender process. The evaluation process considers a competitive review of the capabilities of each potential partner to ensure that the partner ultimately selected can deliver commercial product to the standard required by Cleo, which is largely set by regulatory bodies such as the Food and Drug Administration (FDA) and potential customer groups.

Figure 1: Indicative high-level timeline for the commercial development of Cleo’s ovarian cancer test-kit for the initial Surgical Triage Test market.

 

For more information, or media inquiries, contact:

Elvis Jurcevic
Investor Relations
+61408 268 271
ej@cleodx.com

or

Richard Allman
Chief Executive Officer
+613 9614 0000
office@cleodx.com

 

More from this category

  • Biotechnology, Medical Health Aged Care
  • 22/02/2024
  • 10:36
Neuroscience Research Australia

The neuroscience of attending Taylor Swift’s The Eras Tour: Dr Steve Kassem available to comment

Dr Steve Kassem from Neuroscience Research Australia is available to provide expert commentary on what happens to your brain during, and after, attending one…

  • Contains:
  • Biotechnology
  • 20/02/2024
  • 19:07
Hyris

Hyris Technology Supports the Fight Against One of the World’s Deadliest Diseases, Malaria

Hyris' molecular diagnostic technology has been adapted to enable real-time surveillance of mosquito vector insecticide resistance, which will aid in malaria control campaigns.LONDON, UK / ACCESSWIRE / February 20, 2024 / Hyris, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three or less hours after capture. Current approaches can take up to six months since samples must be collected in remote areas and then…

  • Art, Biotechnology
  • 14/02/2024
  • 11:43
Australian Network for Art & Technology (ANAT)

When art collides with science and technology, magic happens: ANAT Synapse 2024 residents announced

When art collides with science and technology, magic happens ANAT Synapse 2024 residents announced $20,000 Fellowship unveiled celebrating 20 years of art + science…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.